The story of Sildenafil presents a complex picture for investors. While the initial introduction generated significant gains, the lapse of its intellectual property protection opened the door to cheaper alternatives, https://marleyvmda098952.gynoblog.com/40522881/the-copyright-and-big-pharma-a-risky-bet